Medication info
Diapolmin XR 1000mg (Metformin Hydrochloride)

Diapolmin XR 1000mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
White rectangular sustained-release tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201701003 · Approved 2017.02.23 · Insurance code 694001330

Summary

Main use
Treatment of type 2 diabetes mellitus in adults inadequately controlled by diet and exercise
Who takes it
Adults
Adult dose
The dose should be determined individually based on the drug's efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, it should be increased by 500mg each week, up to a maximum of 2000mg per day with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this preparation is the same as the daily dose of immediate-release metformin tablets. Switching to this preparation is not recommended for patients taking more than 2000mg of immediate-release metformin tablets per day. - At the start of treatment and when adjusting the dose, fasting blood glucose should be measured to assess the response to this drug and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this drug, when administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, treatment with this drug should be discontinued immediately.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults inadequately controlled by diet and exercise

  • Poor blood sugar control
  • type 2 diabetes
  • overweight
View approved original text

This medication helps adults with type 2 diabetes, particularly those who are overweight, when blood sugar control is insufficient with diet and exercise alone. It can be used as monotherapy, or in combination with other oral hypoglycemic agents or insulin to enhance blood sugar control. This contributes to stable management of blood sugar levels and helps reduce the occurrence of complications.

How to take

Adult dose

The dose should be determined individually based on the drug's efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, it should be increased by 500mg each week, up to a maximum of 2000mg per day with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this preparation is the same as the daily dose of immediate-release metformin tablets. Switching to this preparation is not recommended for patients taking more than 2000mg of immediate-release metformin tablets per day. - At the start of treatment and when adjusting the dose, fasting blood glucose should be measured to assess the response to this drug and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this drug, when administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, treatment with this drug should be discontinued immediately.

Precautions

This medication can rarely cause a serious condition called lactic acidosis; thus, if such symptoms occur, medical personnel should be notified immediately. Caution is also required when using it along with insulin or sulfonylureas, as low blood sugar may occur. This medication should not be used in patients with moderate to severe renal impairment or acute illnesses that may affect renal function, such as dehydration or serious infections. The use of this medication is prohibited in conditions such as acute heart failure, acute myocardial infarction, and sepsis. It is essential to temporarily discontinue this medication before and after undergoing tests that use iodine-based contrast agents and to resume only after normal kidney function is confirmed. This medication is not administered in cases of hypersensitivity or in patients with type 1 diabetes or diabetic ketoacidosis. Care should be taken when used in patients with infections, pre- or post-surgery, malnutrition, liver dysfunction, or excessive alcohol consumption, and it may potentially be temporarily discontinued until the condition improves. Caution is also needed in cases of irregular or insufficient food intake, intense exercise, or other medications that may interact with this medication. Gastrointestinal disturbances are common during treatment with this medication, and if side effects are severe, a doctor should be consulted. Regular monitoring of kidney function, blood sugar levels, and vitamin B12 levels is necessary, especially in elderly patients or those with reduced kidney function. During pregnancy, fetal growth should be closely monitored, and breastfeeding mothers should consider discontinuing nursing or re-evaluating medication treatment. In case of overdose, visit a medical facility immediately for appropriate treatment, as this medication can be removed by blood dialysis. This medication is not recommended for children, and in elderly patients, dosage should be adjusted according to kidney function. Furthermore, alcohol consumption can increase the risk of lactic acidosis, so patients should not indulge in excessive drinking during treatment. This medication may interact with other diabetes treatments and multiple drugs, so if other medications are being taken, it is essential to inform healthcare personnel. The tablet should be swallowed whole for easier intake, and the tablet shell may be excreted, which is normal. During the course of this medication, regular blood sugar tests and kidney function checks should be conducted to continuously monitor treatment effectiveness and side effects.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • anorexia
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and humidity and should be stored in a tightly sealed container. It is recommended to store it at room temperature, between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White rectangular sustained-release tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.